Teams led by researchers at George Mason University have published a pair of studies exploring protein signaling in breast and colon cancer that could offer new insights into treatments for the diseases.
Technology developed by Lance Liotta and Emanuel Petricoin will be used to find and identify biomarkers for evaluating new investigational therapies for the neoadjuvant-drug study.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
